Biotron Limited has signed a major international partner to assist trialing its Hepatitis C drug, BIT225.
Biotron Limited believes its alliance with the prestigious ACLIRES clinical research group will be critical to its success.
Chief Executive Officer Dr. Michelle Miller said ACLIRES specialised in running clinical trials for both Hepatitis C and the HIV virus, with fully accredited facilities in South America and Asia.
“It has a long history of running successful Phase I and II trials of new drugs, with international pharmaceutical companies and US biotech companies among its clients,” she said.
“ACLIRES also has access to large numbers of eligible patient populations. This really is critical to the successful completion of the trial, as one of the biggest risk factors for trials is access to sufficient suitable patients.”
Unlike other Hepatitis C drugs, Biotron’s drug, BIT 225 works by targeting the p7 protein, a viral protein essential to virus production and replication.
The next stage of development is to determine how the drug works in combination with current approved treatments for HCV, Interferon and Ribavairin.
At its helm of ACLIRES is well regarded infectious diseases expert, Professor Rob Murphy, currently the Director of the Centre for Global Health at the prestigious Northwestern University in Chicago, USA.
Dr Miller added: “We are confident our drug trials are in the best possible position under Professor Murphy’s leadership.”
Date: March 18, 2010
Source: Biotron Limited
Filed Under: Drug Discovery